The original success of the copyright undeniably revolutionized the pharmaceutical landscape, but betting in companies primarily reliant on off-patent versions presents a challenging picture. While early profits were substantial, the cessation of patents and the rise of discounted alternatives have eroded sales. Thus, a thorough evaluation of prese